• Kleyton Santos de Medeiros, Luís Antônio Soares da Silva, Luíza Thomé de Araújo Macêdo, Ayane Cristine Sarmento, Ana Paula Ferreira Costa, José Eleutério, and Ana Katherine Gonçalves.
• Universidade Federal do Rio Grande do Norte, Health Sciences Postgraduate Program, - Natal (RN), Brazil.
• Rev Assoc Med Bras (1992). 2021 Jan 1; 67Suppl 1 (Suppl 1): 127-156.

BackgroundAlthough much has been studied about the SARS-Cov-2 virus, its effects, and the effectiveness of possible treatments, little is known about its interaction with other infectious diseases.ObjectiveThe aim is to study its clinical features and morbidity, and mortality outcomes of COVID-19 patients with HIV/AIDS coinfection.Data SourcesMEDLINE, Web of Science, Embase, CINAHL, LILACS, Scopus, ClinicalTrials.gov, and Cochrane.Study Eligibility CriteriaAtudies in any language, published after 2019, were describing COVID-19 patients with HIV/AIDS.Study AppraisalJBI Levels of Evidence, Joanna Briggs Institute.Synthesis MethodsAs shown in the PRISMA flow diagram, two authors separately screened the search results from the obtained titles and abstracts.ResultsChest CT was observed in patients with pneumonia by SARS-CoV-2 with findings of multiple ground-glass opacities (GGO) in the lungs, there is a need for supplemental oxygenation. One patient developed encephalopathy and complicated tonic-clonic seizures; four patients were transplanted (two, liver; two, kidneys), one patient developed severe SARS-CoV-2 pneumonia and 30 patients died (mortality rate, 11%).ConclusionHIV did not show any relevance directly with the occurrence of COVID-19. Some studies suggest that HIV-1 infection through induction levels of IFN-I, may to some extent, stop the apparent SARS-CoV-2 infection, thus leading to undetectable RNA. Moreover, some authors suggest retroviral therapy routinely used to control HIV infection could be used to prevent COVID-19 infection.

6 keywords...

hide…